LY3541860 for Rheumatoid Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, LY3541860, for individuals with Rheumatoid Arthritis (RA) who haven't responded to other RA medications. It aims to evaluate the effectiveness of LY3541860 in those with moderate to severe symptoms. Participants receive the treatment through an IV (intravenous) and undergo several weeks of monitoring. The trial suits adults diagnosed with RA for at least three months who frequently experience joint swelling and tenderness, particularly in the hands or wrists. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.
Will I have to stop taking my current medications?
The trial requires that you do not change the dose of corticosteroids, opioids, or conventional disease-modifying antirheumatic drugs (cDMARDs) and that you do not take Janus kinase (JAK) inhibitors within 28 days before the screening MRI or during the study.
Is there any evidence suggesting that LY3541860 is likely to be safe for humans?
Research shows that LY3541860 is being tested for safety in treating rheumatoid arthritis. In one study, patients experienced some common side effects, similar to those with other treatments like tofacitinib, another drug for this condition. These side effects are usually mild, but the overall safety of LY3541860 remains under investigation. As a Phase 2 trial, the treatment has already demonstrated some safety in earlier tests. However, ongoing studies will provide more information on its tolerability.12345
Why do researchers think this study treatment might be promising for Rheumatoid Arthritis?
Unlike the standard treatments for rheumatoid arthritis, which typically include oral medications like methotrexate or biologics administered subcutaneously, LY3541860 is administered intravenously. This delivery method might offer more direct and potentially faster relief from symptoms. Researchers are also excited because LY3541860 could introduce a new active ingredient that targets inflammation differently, providing an innovative approach to managing this condition.
What evidence suggests that LY3541860 might be an effective treatment for Rheumatoid Arthritis?
Research has shown that LY3541860, the investigational treatment in this trial, may help treat rheumatoid arthritis. In earlier studies, patients taking LY3541860 experienced noticeable improvements in symptoms, such as reduced joint pain and swelling. Additionally, scores measuring arthritis activity significantly decreased over 48 months. This suggests that LY3541860 could be effective for individuals with moderate to severe rheumatoid arthritis, particularly for those who haven't found success with other treatments.23467
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for adults with moderate to severe Rheumatoid Arthritis who haven't had enough improvement with at least one biologic or synthetic disease-modifying drug. Participants should be able to commit to a 50-week study period.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LY3541860 intravenously for rheumatoid arthritis treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3541860
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University